New York State Teachers Retirement System Purchases 542 Shares of Heska Corp (NASDAQ:HSKA)

Share on StockTwits

New York State Teachers Retirement System lifted its position in shares of Heska Corp (NASDAQ:HSKA) by 13.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,608 shares of the medical research company’s stock after acquiring an additional 542 shares during the period. New York State Teachers Retirement System’s holdings in Heska were worth $429,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Two Sigma Investments LP increased its position in shares of Heska by 2.2% during the first quarter. Two Sigma Investments LP now owns 6,627 shares of the medical research company’s stock valued at $366,000 after acquiring an additional 140 shares in the last quarter. State Street Corp boosted its holdings in Heska by 1.2% in the first quarter. State Street Corp now owns 287,309 shares of the medical research company’s stock worth $15,888,000 after purchasing an additional 3,430 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in Heska by 78.1% in the first quarter. BNP Paribas Arbitrage SA now owns 2,804 shares of the medical research company’s stock worth $155,000 after purchasing an additional 1,230 shares during the last quarter. Royal Bank of Canada boosted its holdings in Heska by 20.3% in the first quarter. Royal Bank of Canada now owns 18,251 shares of the medical research company’s stock worth $1,009,000 after purchasing an additional 3,079 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Heska by 1,858.8% in the first quarter. JPMorgan Chase & Co. now owns 46,267 shares of the medical research company’s stock worth $2,558,000 after purchasing an additional 43,905 shares during the last quarter. 79.67% of the stock is owned by institutional investors.

Shares of Heska stock opened at $96.22 on Friday. The company’s fifty day simple moving average is $92.22 and its 200-day simple moving average is $85.11. The stock has a market capitalization of $903.51 million, a PE ratio of -96.22 and a beta of 1.72. Heska Corp has a 1-year low of $50.00 and a 1-year high of $110.90. The company has a debt-to-equity ratio of 0.19, a current ratio of 11.21 and a quick ratio of 9.89.

Heska (NASDAQ:HSKA) last released its earnings results on Thursday, May 7th. The medical research company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.44). Heska had a negative net margin of 5.99% and a negative return on equity of 1.04%. The firm had revenue of $30.65 million for the quarter, compared to analysts’ expectations of $33.47 million. As a group, research analysts anticipate that Heska Corp will post -0.81 EPS for the current year.

Several brokerages recently issued reports on HSKA. Piper Sandler dropped their target price on shares of Heska from $107.00 to $87.00 in a report on Monday, May 25th. Alliance Global Partners raised their target price on shares of Heska from $78.00 to $90.00 in a report on Friday, May 8th. Zacks Investment Research cut shares of Heska from a “buy” rating to a “hold” rating in a report on Tuesday, June 30th. BidaskClub upgraded shares of Heska from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 25th. Finally, ValuEngine cut shares of Heska from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $81.67.

In related news, CEO Kevin S. Wilson sold 10,000 shares of Heska stock in a transaction on Friday, June 5th. The shares were sold at an average price of $91.00, for a total transaction of $910,000.00. Following the transaction, the chief executive officer now owns 82,955 shares in the company, valued at approximately $7,548,905. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Kevin S. Wilson sold 9,707 shares of Heska stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $89.00, for a total transaction of $863,923.00. Following the transaction, the chief executive officer now owns 82,955 shares in the company, valued at approximately $7,382,995. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,941 shares of company stock worth $2,741,842. 11.70% of the stock is owned by corporate insiders.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Read More: What are the FAANG Stocks?

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SolarWinds  Shares Gap Down  on Insider Selling
SolarWinds Shares Gap Down on Insider Selling
Cronos Group  Shares Gap Up  on Insider Buying Activity
Cronos Group Shares Gap Up on Insider Buying Activity
Research Analysts Set Expectations for Prestige Consumer Healthcare Inc’s Q2 2021 Earnings
Research Analysts Set Expectations for Prestige Consumer Healthcare Inc’s Q2 2021 Earnings
Q2 2021 EPS Estimates for Essex Property Trust Inc  Cut by Analyst
Q2 2021 EPS Estimates for Essex Property Trust Inc Cut by Analyst
Equities Analysts Offer Predictions for Pembina Pipeline Corp’s Q4 2020 Earnings
Equities Analysts Offer Predictions for Pembina Pipeline Corp’s Q4 2020 Earnings
Q4 2020 EPS Estimates for Sykes Enterprises, Incorporated  Raised by Analyst
Q4 2020 EPS Estimates for Sykes Enterprises, Incorporated Raised by Analyst


© 2006-2020 Ticker Report